To examine the utility for γδ T-cell-targeted therapeutics against refractory MDR-TB, each of the studied macaques was infected with 500 CFU of clinical MDR-TB strain V791 as we previously described [10], and were then treated with ZOL/IL-2 (clinical drugs for human diseases) as adjunctive immunotherapy in combination with second-line anti-TB drugs against MDR-TB (Table 1 and Supplemental Table). Here, IL2 is linked to tuberculosis.